After raising US$260 million, Imperative Care hopes to build a portfolio of stroke care companies

As a result of new capital injections, a start-up company with two cleared stroke treatment devices is planning to build a broader technology suite. Imperative Care recently raised $260 million in a round of financing led by D1 Capital Partners and used a portion of the funds to acquire Truvic, a start-up company that manufactures blood clot removal equipment on arms or legs.

Imperative Care was founded in 2015 by Fred Khosravi, the managing partner of a medical technology incubator, and Dr. Nick Hopkins, a neurosurgeon, who pioneered a minimally invasive treatment for stroke. Some patients are eligible for thrombectomy, a minimally invasive procedure that removes blood clots through surgical procedures.

The Campbell, California-based company currently has two devices approved by the U.S. Food and Drug Administration: a catheter used by surgeons to navigate blood vessels in the brain, and a set used to remove clots during ischemic strokes. The device is used when the patient is not eligible to receive “blood clotting” drugs.

Now, through recent acquisitions, Imperative Care plans to develop a wider range of technologies to treat strokes and vascular diseases. First, it plans to further develop and commercialize Truvic’s technology. The company will remain a wholly-owned subsidiary of Imperative and will maintain its leadership position and brand.

“In addition to our initial focus on the stroke area, we also see areas of natural synergy for unmet patient needs, and we are committed to accelerating these commercialization paths,” Khosravi said in a press release. “In order to achieve this goal, starting with Truvic, we are creating a network of wholly-owned subsidiaries that will leverage synergies where appropriate, while giving development projects the independence, professionalism and focus required to bring important Vascular intervention products to meet the needs of patients as soon as possible.”